<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03697720</url>
  </required_header>
  <id_info>
    <org_study_id>EH18-128</org_study_id>
    <nct_id>NCT03697720</nct_id>
  </id_info>
  <brief_title>Examining the Role of Improved NSAID Management in Treating Dysmenorrhea and Bladder Pain</brief_title>
  <official_title>Examining the Role of Improved NSAID Management in Treating Dysmenorrhea and Bladder Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NorthShore University HealthSystem</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NorthShore University HealthSystem</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to see if optimized use of naproxen for treatment of dysmenorrhea&#xD;
      will improve pain report from baseline. In addition, we will determine whether cross-organ&#xD;
      influences from the uterus on bladder pain sensitivity change from baseline after reduced&#xD;
      menstrual pain experience over six months. Finally, a battery of quantitative sensory tests&#xD;
      and EEG measures of sensory sensitivity will be used to evaluate mechanisms associated with&#xD;
      improvements in menstrual and bladder pain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 9, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Menstrual Pain</measure>
    <time_frame>6-8 months</time_frame>
    <description>Daily Diary data on menstrual pain-is it improved with the use of naproxen?</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bladder Pain</measure>
    <time_frame>6-8 months</time_frame>
    <description>Experimental Bladder Pain sensitivity using a naturalistic paradigm-is it improved when menstrual pain is treated with naproxen?</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Dysmenorrhea</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Primary Dysmenorrhea</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We will look at the effects of naproxen 500mg use on pain starting just before and during menses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>Participants will take naproxen 500mg BID before and for the first 3 days of their period.</description>
    <arm_group_label>Primary Dysmenorrhea</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Reproductive-age women (age 18-45) with dysmenorrhea&#xD;
&#xD;
          -  Average menstrual pain â‰¥ 5/10 (0=no pain and 10=the worst imaginable pain) on at least&#xD;
             one day during menses or during withdrawal uterine bleeding from cyclic OCs without&#xD;
             painkillers&#xD;
&#xD;
          -  Menstrual pain in the region between the umbilicus and the perineum, above the level&#xD;
             of the inguinal ligament&#xD;
&#xD;
          -  Indication the participant has attempted to resolve pain by medical means (including&#xD;
             NSAIDs and/or OCPs)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of active pelvic or abdominal malignancies (primary or metastatic)&#xD;
&#xD;
          -  Absence of regular menses (including current pregnancy, recent pregnancy, or active&#xD;
             breast feeding)&#xD;
&#xD;
          -  Active genitourinary infection in the last four weeks&#xD;
&#xD;
          -  Unable to read or comprehend the informed consent in English&#xD;
&#xD;
          -  Unwilling to complete study procedures&#xD;
&#xD;
          -  Presence of hypertension or risk for developing hypertension&#xD;
&#xD;
          -  Unwillingness to take naproxen and/or placebo&#xD;
&#xD;
          -  Contradictions to taking naproxen (allergies, kidney disease, anemia, alcoholism,&#xD;
             cardiovascular disease, stomach or intestinal ulcer or abnormal liver function)&#xD;
&#xD;
          -  Formal urological diagnosis such as overactive bladder or painful bladder syndrome.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Tu, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>NorthShore University HealthSystem</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NorthShore University Health System</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 4, 2018</study_first_submitted>
  <study_first_submitted_qc>October 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2018</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NorthShore University HealthSystem</investigator_affiliation>
    <investigator_full_name>Frank Tu</investigator_full_name>
    <investigator_title>Division Director MIS/Clinical Associate Professor</investigator_title>
  </responsible_party>
  <keyword>cross-organ sensitivity</keyword>
  <keyword>bladder pain</keyword>
  <keyword>NSAID</keyword>
  <keyword>visceral pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysmenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

